BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•05/08/2026•16:50 ET
0
Whiz Insights
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
QUELL-DME, Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, planned to initiate in mid-2026, with data anticipated in mid-2027; results expected to support development across inflammation-driven retinal diseases
Get started
Create a free account to read the full story.